Overview

OPKO Renal is developing proprietary products to treat secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD) and vitamin D insufficiency. These products are designed to treat patients with Stage 3, 4 or 5 CKD, but they also have potential application to other indications including metabolic bone disease, such as renal osteodystrophy and osteoporosis. In addition, the Renal Division is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.

SHPT = Secondary Hyperparathyroidism
CKD = Chronic kidney disease